Tarsus to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026
Globe Newswire•29/10/2026•16:30 ET
0
Key Highlights
- ➤Tarsus will report third quarter 2026 financial results on November 3, 2026
- ➤XDEMVY is FDA approved for treating Demodex blepharitis in the United States
- ➤TP-04 and TP-05 are advancing in Phase 2 development
IRVINE, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Tuesday, November 3, 2026 to report its third quarter 2026 financial results and provide a corporate update.
Participants may access the webcast here. A recorded version of the call will be available on the website shortly after the completion of the webcast and will be archived there for approximately 90 days.
Get started
Create a free account to read the full story.